NCT03368989View on ClinicalTrials.gov

The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.

CompletedOBSERVATIONAL
Enrollment

21

Participants

Timeline

Start Date

February 11, 2014

Primary Completion Date

February 7, 2017

Study Completion Date

February 7, 2017

Conditions
Bony Metastases From Castrate Refractory Prostate Cancer
Interventions
DRUG

Radium-223 dichloride

Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER

NCT03368989 - The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions. | Biotech Hunter | Biotech Hunter